The main goal of this study is to determine how taking efavirenz affects the levels of pitavastatin in the bloodstream when both drugs are taken together and to see how darunavir with ritonavir affects the levels of pitavastatin in the bloodstream. Secondary goals are to see how taking pitavastatin affects the levels in the blood of efavirenz when both drugs are taken together and to see how taking pitavastatin affects the levels in the blood of darunavir.

Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:

AUC of pitavastatin after coadministration of efavirenz. AUC of pitavastatin after coadministration of darunavir with ritonavir. AUC of efavirenz after coadministration of pitavastatin. AUC of darunavir after coadministration of pitavastatin. [ Time Frame: 0 to 24 hours ] [ Designated as safety issue: No ]

24-hour area under the curve (AUC)

Secondary Outcome Measures:

Other pharmacokinetic parameters of pitavastatin and efavirenz and of pitavastatin and darunavir+ritonavir. Lipid measurements at days 0,4,14 and 18. [ Time Frame: 0-24 hours ] [ Designated as safety issue: No ]

Other pharmacokinetic parameters of pitavastatin and efavirenz such as Cmax, Cmin, Tmax, and T1/2.

Other pharmacokinetic parameters of pitavastatin and darunavir+ritonavir such as Cmax, Cmin, Tmax, and T1/2.

At days 0, 4, 14 and 18: Fasting HDL, total cholesterol, LDL and triglycerides for patients in Arm A.

At days 0, 4, 14 and 18: Fasting HDL, total cholesterol, LDL and triglycerides for patients in Arm B.

Absence of HIV-1 infection as documented by any licensed ELISA test kit within 21 days prior to study entry.

Male or female aged 18-60 years.

Able and willing to provide informed consent.

All men and women of reproductive potential must practice adequate birth control to prevent pregnancy from start of the study until completion of the study.

Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to study entry and day of entry.

Hemoglobin > 12.5 g/dL for men; > 11.5 g/dL for women;

Absolute neutrophil count >1,500 cells/mm3;

Platelet count > 100,000 platelets/mm3;

AST (SGOT)/ALT (SGPT) <1.5X ULN;

Creatinine <1.5 X ULN

Subject is within 20% (+/-) of ideal body weight and must weigh at least 50 kg

Exclusion Criteria:

Use of illicit drugs or alcohol which would interfere with the completion of this study.

Pregnancy or breast-feeding.

History of chronic illnesses such as hypertension, coronary artery disease, arthritis, diabetes, or any chronic gastrointestinal conditions which might interfere with drug absorption.

Any medical condition which, in the opinion of the investigator, would interfere with the subjects ability to participate in this protocol.

Use of prohibited protocol-specified drugs, prescription or over-the-counter within 14 days prior to study entry.

Participation in any investigational drug studies within 30 days prior to study entry.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01695954